AU719290B2 - Method for treating Alzheimer's disease - Google Patents

Method for treating Alzheimer's disease Download PDF

Info

Publication number
AU719290B2
AU719290B2 AU52442/98A AU5244298A AU719290B2 AU 719290 B2 AU719290 B2 AU 719290B2 AU 52442/98 A AU52442/98 A AU 52442/98A AU 5244298 A AU5244298 A AU 5244298A AU 719290 B2 AU719290 B2 AU 719290B2
Authority
AU
Australia
Prior art keywords
folate
folic acid
vitamin
drug
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU52442/98A
Other languages
English (en)
Other versions
AU5244298A (en
Inventor
Kim Anthony Jobst
Anthony David Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU5244298A publication Critical patent/AU5244298A/en
Application granted granted Critical
Publication of AU719290B2 publication Critical patent/AU719290B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU52442/98A 1996-11-06 1997-11-04 Method for treating Alzheimer's disease Ceased AU719290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3064296P 1996-11-06 1996-11-06
US60/030642 1996-11-06
PCT/US1997/020021 WO1998019690A1 (en) 1996-11-06 1997-11-04 Method for treating alzheimer's disease

Publications (2)

Publication Number Publication Date
AU5244298A AU5244298A (en) 1998-05-29
AU719290B2 true AU719290B2 (en) 2000-05-04

Family

ID=21855203

Family Applications (1)

Application Number Title Priority Date Filing Date
AU52442/98A Ceased AU719290B2 (en) 1996-11-06 1997-11-04 Method for treating Alzheimer's disease

Country Status (6)

Country Link
US (2) US6008221A (enExample)
EP (1) EP0951293A4 (enExample)
JP (1) JP2001504104A (enExample)
AU (1) AU719290B2 (enExample)
CA (1) CA2270780A1 (enExample)
WO (1) WO1998019690A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566065B1 (en) * 1994-05-26 2003-05-20 Mcgill University Method of diagnosing schizophrenia by detecting a mutation in the (MTHFR) gene
GB9410620D0 (en) 1994-05-26 1994-07-13 Univ Mcgill cDNA for human mehylenetetrahydrofolate reductase
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
US6310052B1 (en) * 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
US6274564B1 (en) 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
ES2238770T5 (es) 1997-10-17 2012-01-17 Ark Therapeutics Limited Utilización de inhibidores del sistema renina-angiotensina para el tratamiento de la hipoxia o de la disminución de la función metabólica.
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
WO2000007566A1 (en) * 1998-08-03 2000-02-17 Epigenesis Pharmaceuticals, Inc. A new analgesic, anti-inflammatory and wound healing agent
CA2348445C (en) * 1998-10-30 2009-12-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions for the treatment and prevention of cardiovascular diseases
JP2002528507A (ja) * 1998-10-30 2002-09-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 神経疾患および病態心理学的疾患の治療および予防用の組成物
DE19913528A1 (de) * 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
WO2000040172A1 (en) * 1999-01-05 2000-07-13 East Carolina University Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
BE1012495A3 (fr) * 1999-03-02 2000-11-07 Messadek Jallal La glycine-betaine pour son usage antithrombotique.
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
WO2000057879A1 (en) * 1999-03-26 2000-10-05 Barry Reisberg Treatment of brain changes with myelin protective agents
WO2001000047A1 (en) * 1999-06-29 2001-01-04 The New Zealand Milk Institute Limited Prophylactic dietary supplement based on milk
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
AU1243101A (en) * 1999-10-28 2001-05-08 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
DE10004651A1 (de) * 2000-02-03 2001-08-16 Jutta Dierkes Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen
US7442689B2 (en) 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
CA2406077C (en) * 2000-04-10 2010-07-20 Nicholas J. Wald Formulation for the prevention of cardiovascular disease
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE10022510A1 (de) * 2000-05-10 2001-11-15 Basf Ag Zusammensetzungen enthaltend Folsäure und reduziertes Folat
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
JP2004538262A (ja) * 2000-12-14 2004-12-24 タフツ ユニバーシティー 関節炎状態を治療するための化合物および方法
US6537992B2 (en) * 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
BR0101088A (pt) * 2001-03-19 2003-03-18 Biolab Sanus Farmaceutica Ltda Processo de isolamento e purificação de peptìdeos inibidores das vasopeptidases, com especificidade para o sìtio carboxìlico da enzima conversora da angiotensina, secretados pelas glândulas do veneno de serpentes (bpps), particularmente bothrops jararaca, ou produzidos endogenamente (evasins) possuindo ação vasodilatadora e anti-hipertensiva; processo de determinação da sequência de amido-ácidos dos peptìdios inibidores secretados pela glândula de veneno de serpentes (bpps) ou endógenos (evasins); processo de determinação da sequência de aminoácidos dos bpps por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca. processo de determinação da sequência de aminoácidos dos evasins por dedução do cdna dos precursores dessas moléculas expressos em tecidos de serpentes, especificamente bothrops jararaca, processo de amplificação do cdna a partir das bibliotecas de cdna de pâncreas e/ou cérebro de serpentes, especificamente bothrops jararaca; processo de sìntese em fase sólida de peptìdeos inibidores das vasopeptidases com ação vasodilatadora e anti-hipertensiva, peptìdeos inibidores das vasopeptidases com ação anti-hipertensiva; utilização dos peptìdeos inibidores das vaso peptidases com ação vasodilatadora e anti-hipertensiva na obtenção de composições farmacêuticas; processo de determinação da atividade inibitória sobre as vasopeptidases e de atividade biológica sobre músculo liso, sistema cardiovascular e microcirculatório.
ES2269671T3 (es) * 2001-04-25 2007-04-01 Cobalz Limited Composiciones medicas para su uso en el tratamiento o la prevencion de una insuficiencia de vitamina b12 funcional.
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
WO2003000381A1 (en) 2001-06-25 2003-01-03 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US7319145B2 (en) * 2001-12-03 2008-01-15 Rima Rozen Methylenetetrahydrofolate reductase inhibitors and use thereof
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20040162292A1 (en) * 2002-12-03 2004-08-19 Evenstad Kenneth L. Multivitamin formulations for promoting healthy collagen, and methods of their use
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US6951658B1 (en) * 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
WO2005011736A1 (ja) * 2003-07-30 2005-02-10 Tohoku Techno Arch Co., Ltd. アルツハイマー病の予防および／または治療剤
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
US20050032740A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin compositions for the treatment and prevention of vascular disease and dementia
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
EP1645276A1 (en) * 2004-10-08 2006-04-12 Wageningen Centre for Food Sciences Treatment of neurodegenerative disorders
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
EP2242489A1 (en) 2005-02-15 2010-10-27 Jallal Messadek Combination therapeutic compositions and method of use
RU2007143510A (ru) 2005-04-27 2009-06-10 Яллал МЕССАДЕК (BE) Инсулиновые композиции
US20070010492A1 (en) * 2005-07-11 2007-01-11 Generale Robert J Composition and method for reducing homocysteine caused by drugs containing methyl compounds
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
AU2008227465B2 (en) * 2007-03-22 2014-02-06 Magceutics, Inc. Magnesium compositions and uses thereof
GB0715502D0 (en) * 2007-08-08 2007-09-19 Univ Manchester Methods
JP5376785B2 (ja) * 2007-09-28 2013-12-25 小林製薬株式会社 医薬組成物
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
JP5584411B2 (ja) * 2007-12-27 2014-09-03 サントリーホールディングス株式会社 ホモシステイン低下用組成物
BR112013000027A2 (pt) 2010-07-01 2017-07-11 Isis Innovation tratamento de distúrbios cognitivos
US20150065449A1 (en) 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
US20150065448A1 (en) * 2011-08-12 2015-03-05 The Florida State University Research Foundation Inc. Methods of treating amyloidoses with vitamin b12 and diagnostic test for detecting the presence of amyloid-beta peptides
CN103386130A (zh) * 2013-06-27 2013-11-13 深圳奥萨医药有限公司 Ace抑制剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物及用途
US10661099B2 (en) * 2015-06-16 2020-05-26 Eugene R. Moore Treatment of alzheimer's disease
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US10201577B2 (en) 2017-02-14 2019-02-12 Keyview Labs, Inc. Compositions and methods for enhancing working and long-term memory support using new combination of ginkgo biloba and panax ginseng and associated components
JP7550448B2 (ja) 2017-11-22 2024-09-13 エイチディーエル セラピューティクス インコーポレイテッド 血漿処理システムの流体回路をプライミングするシステムおよび方法
AU2018396009A1 (en) 2017-12-28 2020-07-16 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11547688B2 (en) * 2019-08-22 2023-01-10 Nodari Rizun Amino acid compositions and methods of manufacturing the compositions
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595005A1 (en) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Pharmaceutical preparations for lowering homocysteine levels, containing vitamin B6, folic acid and vitamin B12

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563126A (en) * 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
ES2134804T3 (es) * 1991-04-19 1999-10-16 Childrens Medical Center Uso de un compuesto generador de oxido nitrico para prevenir daño neuronal.
AP387A (en) * 1991-09-13 1995-07-31 Siegbert Heinrich Bissbort Therapeutical uses of L-methionine and compositions thereof.
DE4326675C2 (de) * 1993-08-09 1996-12-12 Puetter Medice Chem Pharm Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Vorbeugung von Nervendegenerationserkrankungen und Altersdementia
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0595005A1 (en) * 1992-09-14 1994-05-04 Vesta Medicines (Proprietary) Limited Pharmaceutical preparations for lowering homocysteine levels, containing vitamin B6, folic acid and vitamin B12

Also Published As

Publication number Publication date
AU5244298A (en) 1998-05-29
US6127370A (en) 2000-10-03
CA2270780A1 (en) 1998-05-14
US6008221A (en) 1999-12-28
JP2001504104A (ja) 2001-03-27
EP0951293A4 (en) 2002-06-26
WO1998019690A1 (en) 1998-05-14
EP0951293A1 (en) 1999-10-27

Similar Documents

Publication Publication Date Title
US6127370A (en) Method for treating alzheimer's disease
Abdallah Review on anti-alzheimer drug development: approaches, challenges and perspectives
González-Gross et al. Nutrition and cognitive impairment in the elderly
Zhang et al. Hyperhomocysteinemia increases β-amyloid by enhancing expression of γ-secretase and phosphorylation of amyloid precursor protein in rat brain
Lippi et al. Homocysteine and migraine. A narrative review
Aisen et al. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease
US8598171B2 (en) Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
George et al. Potential therapeutic antipsychotic effects of Naringin against ketamine-induced deficits in rats: involvement of Akt/GSK-3β and Wnt/β-catenin signaling pathways
EP2882304A1 (en) Multi-component formulation for improving neurological function
Bottiglieri et al. Plasma total homocysteine levels and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene: a study in an Italian population with dementia
US20120309723A1 (en) Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
Morawe et al. Pharmacological mTOR-inhibition facilitates clearance of AD-related tau aggregates in the mouse brain
Bonda et al. Novel therapeutics for Alzheimer's disease: an update
US20120149685A1 (en) Composition and method for the treatment of tauopathies
Sanderson et al. PKR-like endoplasmic reticulum kinase (PERK) activation following brain ischemia is independent of unfolded nascent proteins
Yoon et al. Methotrexate decreases PP2A methylation and increases tau phosphorylation in neuron
Navakkode et al. Alpha‐Ketoglutarate ameliorates synaptic plasticity deficits in APP/PS1 mice model of Alzheimer's disease
Wojsiat et al. Familial Alzheimer’s disease lymphocytes respond differently than sporadic cells to oxidative stress: upregulated p53-p21 signaling linked with presenilin 1 mutants
CA2906164A1 (en) Methods for identifying neuroprotective pkc activators
Flemming et al. Hyperhomocysteinemia in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Wang Vitamin B12, folate, and Alzheimer's disease
Al-Soufi et al. Evaluating some biochemical parameters after repeated orally administration of levofloxacin in male rats
Shea et al. 17 β-Estradiol alleviates synergistic oxidative stress resulting from folate deprivation and amyloid-β treatment
Miller Folate, cognition, and depression in the era of folic acid fortification
US20240342111A1 (en) Isomer-specific neuroprotective effect of natural reservatrol

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)